Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. 1998 [classical article]

Neurology. 2001 Dec;57(12 Suppl 5):S46-53.
No abstract available

Publication types

  • Biography
  • Classical Article
  • Historical Article

MeSH terms

  • Adjuvants, Immunologic / history*
  • Adjuvants, Immunologic / therapeutic use
  • Disability Evaluation
  • Glatiramer Acetate
  • History, 20th Century
  • Humans
  • Injections, Subcutaneous
  • Long-Term Care
  • Multiple Sclerosis, Relapsing-Remitting / history*
  • Multiple Sclerosis, Relapsing-Remitting / therapy
  • Peptides / history*
  • Peptides / therapeutic use
  • Randomized Controlled Trials as Topic / history

Substances

  • Adjuvants, Immunologic
  • Peptides
  • Glatiramer Acetate

Personal name as subject

  • K P Johnson
  • B R Brooks
  • J A Cohen
  • C C Ford
  • J Goldstein
  • R P Lisak
  • L W Myers
  • H S Panitch
  • J W Rose
  • R B Schiffer
  • T Vollmer
  • L P Weiner
  • J S Wolinsky